News
PKTX
0.0050
0.00%
0.0000
Weekly Report: what happened at PKTX last week (1124-1128)?
Weekly Report · 5d ago
Weekly Report: what happened at PKTX last week (1117-1121)?
Weekly Report · 11/24 09:18
ProtoKinetix Updates on AAGP® Molecule Progress
TipRanks · 11/21 17:17
ProtoKinetix Appoints Michael Guzzetta as New CEO
TipRanks · 11/17 13:57
Weekly Report: what happened at PKTX last week (1110-1114)?
Weekly Report · 11/17 09:18
Weekly Report: what happened at PKTX last week (1103-1107)?
Weekly Report · 11/10 09:17
Weekly Report: what happened at PKTX last week (1027-1031)?
Weekly Report · 11/03 09:17
Weekly Report: what happened at PKTX last week (1020-1024)?
Weekly Report · 10/27 09:18
Weekly Report: what happened at PKTX last week (1013-1017)?
Weekly Report · 10/20 09:18
Weekly Report: what happened at PKTX last week (1006-1010)?
Weekly Report · 10/13 09:18
ProtoKinetix Increases Authorized Shares to 600 Million
Barchart · 10/11 16:18
Weekly Report: what happened at PKTX last week (0929-1003)?
Weekly Report · 10/06 09:17
Weekly Report: what happened at PKTX last week (0922-0926)?
Weekly Report · 09/29 09:18
Weekly Report: what happened at PKTX last week (0915-0919)?
Weekly Report · 09/22 09:18
Weekly Report: what happened at PKTX last week (0908-0912)?
Weekly Report · 09/15 11:48
Weekly Report: what happened at PKTX last week (0901-0905)?
Weekly Report · 09/08 11:50
Weekly Report: what happened at PKTX last week (0825-0829)?
Weekly Report · 09/01 11:44
Weekly Report: what happened at PKTX last week (0818-0822)?
Weekly Report · 08/25 11:58
Weekly Report: what happened at PKTX last week (0811-0815)?
Weekly Report · 08/18 11:48
More
Webull provides a variety of real-time PKTX stock news. You can receive the latest news about Protokinetix Inc through multiple platforms. This information may help you make smarter investment decisions.
About PKTX
ProtoKinetix, Incorporated is a research and development stage biotechnology company. Company is focused on scientific medical research of Anti-Freeze Glycoproteins (AFGPs) or anti-aging glycoproteins. The Company’s anti-aging glycopeptide is for ophthalmology, dermatology, transplant support and biomanufacturing. The commercial applications for AAGPs include various health care solutions. The Company has not developed a commercially viable product and has not generated any revenue.